r/CanadaStocks

Most people who followed $CYDY remember March 30, 2021. The FDA publicly stated that CytoDyn's claims about leronlimab were "misleading and not supported by the data", no benefit was shown in COVID-19 treatment trials. The stock dropped 25%+ that day.

What happened afterward was a class action lawsuit covering investors who held $CYDY between March 27, 2020 and March 30, 2022.

A $500,000 settlement has been reached and terms are now submitted to the court for approval.

Who qualifies?

Anyone who held $CYDY during the class period and suffered losses from the alleged misrepresentations about leronlimab's effectiveness for HIV and COVID-19.

Can I still apply?

Yes, you can submit your application now and it will be processed once claims filing officially opens after court approval.

If you were damaged by this don't forget to check your eligibility. GL!

Data via TSXInsider.com — open-market purchases. Not financial advice...

1. Blue Moon Metals (MOON.V)
👤 Christian Kargl-Simard — CEO
💰 $281,280 CAD combined | two buys (21,200 sh @ $6.80, then 20,000 sh @ $6.86) | +3% stake
CEO bought on back-to-back days this week, right after the company reported strong development momentum on its Norwegian zinc-copper projects.

2. Standard Lithium (SLI.V)
👤 Michael Barman — Chief Development Officer ($102,732 CAD, +22% stake)
👤 David Park — CEO ($98,437 USD, +3% stake)
📍 Near 52-week low
CDO and CEO both buying the same week, right at the lows, as the company presented its "de-risked push toward 2029" at the Lytham Partners conference.

3. Pembina Pipeline (PPL.TO)
👤 Jaret Sprott — COO
💰 $178,472 CAD | 2,800 shares @ $63.74 | +5% stake
COO buying as Pembina continues building out its role in the Canada-Alberta crude pipeline project.

4. Trican Well Service (TCW.TO)
👤 Stuart O'Connor — Director
💰 $121,044 CAD | 20,000 shares @ $6.05 | +320% stake
Director more than quadrupled his position days after the company renewed its share buyback program — despite shares having pulled back on a Q2 earnings miss.

5. MCAN Mortgage (MKP.TO)
👤 Brian Chu — Director
💰 $120,762 CAD | 5,700 shares @ $21.19 | +137% stake
📍 Near 52-week low
Director more than doubling his stake even as mortgage rates climb toward 3-year highs — a sector headwind for MCAN's lending book.